June 2025 - BioMedWire (BMW)

FridayJun 06, 2025 12:00 pm

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS),…

FridayJun 06, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available. The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency. Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective…

FridayJun 06, 2025 10:00 am

More American Doctors are Relocating to Canada, Citing Federal Government Issues

As U.S. news outlets focus on the economic turmoil triggered by tariffs, another story is quietly developing. More doctors trained and working in the U.S. are relocating to Canada and the reasons they are giving rotate around the actions and policies of the Trump administration. Michael, a pseudonym, is one such doctor who left the U.S. to work in Canada. He says America is changing into a country that steps on the vulnerable and weak, in contrast to the training which makes physicians kind to individuals during their weakest moments. For him, the turning point was when a mob stormed…

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

ThursdayJun 05, 2025 10:00 am

Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation

When inflammatory bowel disease becomes chronic, it is difficult to treat and comes with the likelihood of various complications, such as the onset of bowel cancer. This disease in its chronic form manifests as Crohn’s disease or ulcerative colitis. These diseases particularly impact young people. Early diagnosis followed by treatment is crucial in these cases. A recent study whose findings appeared in the Nature Immunology journal has unveiled a therapeutic target capable of significantly putting the brakes on the processes behind the chronic inflammation underlying inflammatory bowel disease. The research was conducted by a team based at Charite-Universitatsmedizin Berlin. Professor…

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against…

WednesdayJun 04, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

NTRB listed on the Nasdaq in 2021, is trading above its IPO price, and hit an all-time high of $11.78 in January of this year Nutriband’s AVERSA abuse-deterrent patch technology is FDA-bound and could command a market potential as high as $800 million annually Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook. As is typical, the topic of the article focused on Nutriband’s…

TuesdayJun 03, 2025 10:00 am

Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis

A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed. Cancer among children is now regarded to be a worldwide disease burden, and getting an early diagnosis has been made a priority. The researchers undertook their study in order to enable the broader research community to get an understanding of what kids and young people go through starting with the onset of symptoms to the point at which a cancer diagnosis is made. To this end, the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Month: June 2025

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

More American Doctors are Relocating to Canada, Citing Federal Government Issues

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search